Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Spacing anti-TNF doses in rheumatoid arthritis remission or low disease activity
2007-004483-41Phase 3Active
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Aug 2010
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised trial of etanercept and adalimumab in rheumatoid arthritis (RA) (2 arms), sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoint: Inflammatory disease activity equivalence over 18 months. Started Aug 2010; status: active.
02
Drugs
etanerceptadalimumab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2007-004483-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-004483-41.